[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DZ3358A1 - Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression - Google Patents

Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression

Info

Publication number
DZ3358A1
DZ3358A1 DZ003358A DZ003358A DZ3358A1 DZ 3358 A1 DZ3358 A1 DZ 3358A1 DZ 003358 A DZ003358 A DZ 003358A DZ 003358 A DZ003358 A DZ 003358A DZ 3358 A1 DZ3358 A1 DZ 3358A1
Authority
DZ
Algeria
Prior art keywords
dosers
pharmaceutical solution
solution formulations
pressure inhaler
inhaler
Prior art date
Application number
DZ003358A
Other languages
English (en)
Inventor
David Lewis
David Ganderton
Brian Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8163952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of DZ3358A1 publication Critical patent/DZ3358A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DZ003358A 2000-05-22 2000-05-22 Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression DZ3358A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2000/004635 WO2001089480A1 (fr) 2000-05-22 2000-05-22 Preparation en solution pharmaceutique stable pour aerosols-doseurs sous pression

Publications (1)

Publication Number Publication Date
DZ3358A1 true DZ3358A1 (fr) 2001-11-29

Family

ID=8163952

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003358A DZ3358A1 (fr) 2000-05-22 2000-05-22 Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression

Country Status (41)

Country Link
US (3) US6716414B2 (fr)
EP (4) EP1787639B1 (fr)
JP (1) JP5392880B2 (fr)
CN (1) CN1213732C (fr)
AR (1) AR029523A1 (fr)
AT (4) ATE415945T1 (fr)
AU (2) AU2000250701B2 (fr)
BE (1) BE2011C032I2 (fr)
BG (1) BG65883B1 (fr)
BR (1) BR0015884A (fr)
CA (1) CA2411047C (fr)
CY (6) CY1108833T1 (fr)
CZ (1) CZ303833B6 (fr)
DE (5) DE122009000035I1 (fr)
DK (4) DK1787639T3 (fr)
DZ (1) DZ3358A1 (fr)
EA (1) EA005179B1 (fr)
EE (1) EE05167B1 (fr)
ES (4) ES2318217T3 (fr)
FR (1) FR11C0041I2 (fr)
HK (1) HK1058900A1 (fr)
HR (1) HRP20021025B1 (fr)
HU (2) HU230804B1 (fr)
IL (2) IL152955A0 (fr)
JO (1) JO2310B1 (fr)
LT (1) LTC1787639I2 (fr)
LU (1) LU91875I2 (fr)
ME (2) ME00220B (fr)
MX (1) MXPA02011414A (fr)
MY (2) MY127145A (fr)
NL (1) NL300393I2 (fr)
NO (3) NO342935B1 (fr)
PE (1) PE20011323A1 (fr)
PT (4) PT1157689E (fr)
SA (1) SA01220126B1 (fr)
SI (4) SI1787639T1 (fr)
SK (1) SK286694B6 (fr)
TN (1) TNSN01074A1 (fr)
TW (1) TWI284047B (fr)
UA (1) UA73986C2 (fr)
WO (1) WO2001089480A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196432A1 (fr) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Modulateurs du récepteur de la chimiokine et leurs utilisations

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
DE60017450T2 (de) * 1999-11-23 2006-03-02 Glaxo Group Ltd., Greenford Pharmazeutische formulierungen enthaltend salmeterol
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
JP2003534063A (ja) * 2000-05-23 2003-11-18 グラクソ グループ リミテッド キシナホ酸サルメテロール製剤のエアゾル容器
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
EP1241113A1 (fr) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient
SK286394B6 (sk) * 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
EP1415647A1 (fr) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Beta-2-agonistes à activité de longue durée dans une formulation ultrafine
GEP20063986B (en) * 2002-03-01 2006-12-11 Chiesi Farma Spa Formoterol superfine formulation
WO2004022052A1 (fr) * 2002-08-14 2004-03-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation aerosol pour l'inhalation contenant un anticholinergique
US20040166065A1 (en) 2002-08-14 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation comprising an anticholinergic
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
EP1452179A1 (fr) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
US20050003024A1 (en) * 2003-03-04 2005-01-06 The Procter & Gamble Company Regulation of mammalian hair growth
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE526967T1 (de) * 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EP1654001A2 (fr) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medicament pour inhalation comprenant des steroides et un betamimetique
WO2005025550A1 (fr) * 2003-09-15 2005-03-24 Vectura Limited Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
CN100457087C (zh) * 2004-02-27 2009-02-04 奇斯药制品公司 用于加压计量吸入器的稳定的药用溶液制剂
CA2565747A1 (fr) * 2004-05-13 2005-12-01 Chiesi Farmaceutici S.P.A. Produits de formulation d'aerosol medicinale a stabilite chimique amelioree
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
AU2006218177B2 (en) * 2005-02-25 2012-04-12 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
EP1879620A2 (fr) * 2005-03-30 2008-01-23 Schering Corporation Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee
DE102005055960A1 (de) * 2005-11-24 2007-07-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0613761D0 (en) * 2006-07-11 2006-08-23 Norton Healthcare Ltd A pharmaceutical formulation and method for the preparation thereof
EP1982709A1 (fr) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US20090208424A1 (en) * 2008-02-19 2009-08-20 Todd Maibach Compositions and methods for delivery of solution to the skin
EP2257172A4 (fr) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc Procédé et système permettant de traiter la bronchopneumopathie chronique obstructive au moyen d'administrations d'anticholinergiques par nébulisation
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2355808A4 (fr) * 2008-10-23 2012-04-25 Sunovion Pharmaceuticals Inc Compositions d arformotérol et de tiotropium et leurs procédés d'utilisation
EP2201934A1 (fr) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP3508239B1 (fr) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adaptateur, dispositif d'inhalation et pulvérisateur
DK2482799T3 (da) * 2009-10-02 2014-09-01 Chiesi Farma Spa Farmaceutiske aerosolformuleringer af formoterol og beclometasondipropionat
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011084316A2 (fr) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations et procédés pour le réglage de l'administration de particules d'une certaine taille dans un aérosol-doseur
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
ES2464520T3 (es) 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
WO2011160932A1 (fr) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nébuliseur
WO2012010854A1 (fr) 2010-07-23 2012-01-26 Cipla Limited Composition pharmaceutique
WO2012130757A1 (fr) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Appareil médical pourvu d'un récipient
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013019730A1 (fr) 2011-07-29 2013-02-07 The Washington University Anticorps dirigés contre la tip-1 et la grp78
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) * 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
LT3089735T (lt) 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10716907B2 (en) 2014-05-07 2020-07-21 Boehringer Ingelheim International Gmbh Nebulizer
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
PL3139984T3 (pl) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizator
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
CN104225739A (zh) * 2014-09-30 2014-12-24 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
BR112018011266B1 (pt) 2015-12-04 2023-11-21 Mexichem Fluor S.A. De C.V. Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2018148595A1 (fr) 2017-02-10 2018-08-16 Washington University Anticorps dirigés contre tip1 et leurs procédés d'utilisation
WO2019236559A1 (fr) 2018-06-04 2019-12-12 Lupin Inc. Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
WO2020152548A1 (fr) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Compositions pour inhalation d'aérosol stables à base de formotérol
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021110239A1 (fr) * 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Boîte en acier inoxydable pour inhalateurs doseurs sous pression
WO2021151857A1 (fr) 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Inhalateurs doseurs sous pression comprenant une formulation pharmaceutique tamponnée
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
GB2593970B (en) 2020-02-20 2024-09-04 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11642372B2 (en) * 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
CA3186956A1 (fr) 2020-07-31 2022-02-03 Chemo Research , S.L. Polytherapie destinee a une administration par inhalation
CN116419749A (zh) * 2020-10-09 2023-07-11 奇斯药制品公司 用于加压定量吸入器的药物制剂
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
WO2023227783A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur sous pression
WO2023227782A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur pressurisé

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
CA2098298A1 (fr) 1990-12-19 1992-06-20 Susan M. Milosovich Formulations en aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
EP0585379B1 (fr) 1991-05-21 1998-09-30 Abbott Laboratories Dispositif d'inhalation en aerosol
BR9206422A (pt) 1991-08-29 1995-10-17 Christoph Klein Aparelho médico para a inalação de aerossóis dosados
NZ244439A (en) 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ES2216800T3 (es) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
ES2129117T3 (es) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014490A1 (fr) 1992-12-23 1994-07-07 Bernhard Hugemann Bloc de medicament sous forme compactee pour la production de particules inhalables de substance active
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
EP0689423B1 (fr) * 1993-03-17 1997-09-17 Minnesota Mining And Manufacturing Company Formulation aerosol contenant un agent de dispersion derive d'un diol/diacide
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
ES2145254T3 (es) 1993-12-20 2000-07-01 Minnesota Mining & Mfg Formulaciones de aerosoles que contienen flunisolida.
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
AP791A (en) 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
EE04005B1 (et) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Salmeterooli doseeriv inhalaator
US6149892A (en) * 1995-04-14 2000-11-21 Glaxowellcome, Inc. Metered dose inhaler for beclomethasone dipropionate
EP1769819A3 (fr) 1995-04-14 2013-05-22 GlaxoSmithKline LLC Inhalateur doseur de propionate fluticasone
US6135628A (en) * 1995-10-13 2000-10-24 Boehringer Ingelheim Pharmceuticals, Inc. Method and apparatus for homogenizing aerosol formulations
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (ja) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
WO1998003533A1 (fr) 1996-07-24 1998-01-29 Oligos Etc. And Oligos Therapeutics, Inc. Oligonucleotides anti-sens utilises comme agents antibacteriens
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
ATE301991T1 (de) * 1996-12-04 2005-09-15 Link Products Ltd Arzneimittel zusammensetzungen und vorrichtungen zu deren verabreichung
DE59804534D1 (de) * 1997-02-05 2002-07-25 Jago Res Ag Muttenz Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6000537A (en) * 1997-06-10 1999-12-14 U.S. Philips Corporation Housing with readable side walls for a disc-shaped information carrier
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6324827B1 (en) * 1997-07-01 2001-12-04 Bp Corporation North America Inc. Method of generating power in a dry low NOx combustion system
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU2081999A (en) * 1998-01-13 1999-08-02 Astrazeneca Uk Limited Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
AU759222B2 (en) * 1998-06-18 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
AU748867B2 (en) * 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
EA003960B1 (ru) * 1998-10-17 2003-10-30 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Устойчивый при хранении концентрат биологически активного вещества формотерола
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
ATE382386T1 (de) * 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
WO2001047493A1 (fr) 1999-12-24 2001-07-05 Glaxo Group Limited Formulation pharmaceutique en aerosol de salmeterol et de propionate de fluticasone
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
GEP20063986B (en) * 2002-03-01 2006-12-11 Chiesi Farma Spa Formoterol superfine formulation
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196432A1 (fr) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Modulateurs du récepteur de la chimiokine et leurs utilisations

Also Published As

Publication number Publication date
PT1157689E (pt) 2009-03-23
EP1466594A2 (fr) 2004-10-13
NO342935B1 (no) 2018-09-03
DK2223682T3 (da) 2012-03-19
SI2223682T1 (sl) 2012-04-30
US20020025299A1 (en) 2002-02-28
PT2223682E (pt) 2012-03-22
CN1213732C (zh) 2005-08-10
DE122011100049I1 (de) 2012-01-19
EE200200649A (et) 2004-06-15
HUP0302007A2 (hu) 2003-09-29
ES2318217T3 (es) 2009-05-01
SI1466594T1 (sl) 2009-06-30
WO2001089480A1 (fr) 2001-11-29
CY2009009I1 (el) 2014-04-09
EP1157689B1 (fr) 2009-01-07
ME00220B (me) 2010-10-10
BE2011C032I2 (fr) 2020-08-20
AU2000250701A1 (en) 2002-02-21
HK1058900A1 (en) 2004-06-11
FR11C0041I1 (fr) 2011-04-11
NO2019030I1 (no) 2019-07-11
ATE419832T1 (de) 2009-01-15
CN1452479A (zh) 2003-10-29
US7018618B2 (en) 2006-03-28
TWI284047B (en) 2007-07-21
UA73986C2 (uk) 2005-10-17
DE60137282D1 (de) 2009-02-26
LTC1787639I2 (lt) 2021-05-25
SI1157689T1 (sl) 2009-06-30
DE60136864D1 (de) 2009-01-15
MXPA02011414A (es) 2003-06-06
US20060083693A1 (en) 2006-04-20
ES2380790T3 (es) 2012-05-18
PL359149A1 (en) 2004-08-23
JP2003534266A (ja) 2003-11-18
FR11C0041I2 (fr) 2015-09-04
NL300393I1 (en) 2009-09-01
SI1787639T1 (sl) 2011-07-29
EP1466594B1 (fr) 2008-12-03
HRP20021025B1 (hr) 2013-11-22
NO20025568D0 (no) 2002-11-20
EP1466594A3 (fr) 2004-12-01
ATE415945T1 (de) 2008-12-15
ATE502624T1 (de) 2011-04-15
EE05167B1 (et) 2009-06-15
CY2011014I1 (el) 2015-10-07
ES2359991T3 (es) 2011-05-30
EA005179B1 (ru) 2004-12-30
ATE541563T1 (de) 2012-02-15
CA2411047A1 (fr) 2001-11-29
HU230804B1 (hu) 2018-06-28
LU91875I2 (fr) 2011-11-21
AU2000250701B2 (en) 2004-07-01
CY2011014I2 (el) 2015-10-07
BR0015884A (pt) 2003-07-08
MY143733A (en) 2011-07-15
DK1157689T3 (da) 2009-03-16
CY1108968T1 (el) 2014-04-09
MEP32108A (en) 2010-10-10
NL300393I2 (en) 2010-02-01
DE122009000035I1 (de) 2009-11-05
EP1157689A1 (fr) 2001-11-28
HRP20021025A2 (en) 2004-02-29
IL152955A (en) 2010-02-17
DK1787639T3 (da) 2011-05-09
CZ20023835A3 (cs) 2003-04-16
SK286694B6 (sk) 2009-03-05
BG65883B1 (bg) 2010-04-30
DK1466594T3 (da) 2009-03-02
ES2320194T3 (es) 2009-05-20
LTPA2011011I1 (lt) 2019-08-26
AR029523A1 (es) 2003-07-02
HUP0302007A3 (en) 2006-07-28
CY2009009I2 (el) 2014-04-09
CZ303833B6 (cs) 2013-05-22
AU5070100A (en) 2001-12-03
EP1787639A2 (fr) 2007-05-23
TNSN01074A1 (fr) 2005-11-10
CA2411047C (fr) 2009-08-04
HUS1800032I1 (hu) 2018-08-28
SK16522002A3 (sk) 2003-04-01
PT1787639E (pt) 2011-06-08
NO2019003I1 (no) 2019-01-16
DE60144304D1 (de) 2011-05-05
PE20011323A1 (es) 2002-01-22
NO20025568L (no) 2002-11-20
EP2223682A1 (fr) 2010-09-01
EP2223682B1 (fr) 2012-01-18
PT1466594E (pt) 2009-02-13
CY1108833T1 (el) 2014-07-02
MY127145A (en) 2006-11-30
CY1111570T1 (el) 2015-10-07
CY1113028T1 (el) 2016-04-13
EP1787639B1 (fr) 2011-03-23
IL152955A0 (en) 2003-06-24
JO2310B1 (en) 2005-09-12
US20040047809A1 (en) 2004-03-11
US6716414B2 (en) 2004-04-06
JP5392880B2 (ja) 2014-01-22
BG107256A (bg) 2003-06-30
SA01220126B1 (ar) 2007-04-03
EA200201058A1 (ru) 2003-04-24
EP1787639A3 (fr) 2009-02-25

Similar Documents

Publication Publication Date Title
DZ3358A1 (fr) Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
NO20030418L (no) Nytt farmasöytisk preparat
EP1383376A4 (fr) Formulations pharmaceutiques a liberation prolongee
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
MA27107A1 (fr) Formulations aerosoles pour l'administration pulmonaire de medicaments visant a produire un effet systemique.
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
FR2802423B1 (fr) Compositions pharmaceutiques
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
IS6021A (is) Lyfjasamsetningar sem innihalda sítalópram
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
AU2002346457A8 (en) Pharmaceutical formulations comprising indolinone derivatives
PL359552A1 (en) Flask for medicinal preparations
MA27689A1 (fr) Forme galenique orale pour la liberation controlee de medicament
NO20032957L (no) Farmasöytisk emulsjonspreparat
FR2808977B1 (fr) Orthese dynamique bifonctionnelle pour chaussures
GB0014851D0 (en) Novel pharmaceutical formulation